Jiangsu wuzhong(600200)2015-08-25 16:00Financial Performance - The company's operating revenue for the first half of 2015 was CNY 1,378,986,431.86, a decrease of 9.94% compared to CNY 1,531,206,971.02 in the same period last year[16]. - The net profit attributable to shareholders for the first half of 2015 was CNY 17,402,929.08, representing an increase of 3.28% from CNY 16,850,581.04 in the previous year[16]. - The gross profit for the first half of 2015 was CNY 190.08 million, a decline of CNY 45.63 million or 19.36% year-on-year, with the main business gross profit decreasing by 21.30%[24]. - The total profit for the reporting period was 46.14 million RMB, a decrease of 25.81% compared to the same period last year, which was 62.19 million RMB[36]. - The company achieved a gross profit of 190.08 million RMB, down 19.43% year-on-year, primarily due to a decrease in real estate project handovers[36]. Cash Flow and Investments - The net cash flow from operating activities was negative at CNY -130,688,819.65, an improvement from CNY -171,389,993.40 in the same period last year[16]. - The company’s cash flow from investment activities was CNY 15.79 million, a turnaround from a negative cash flow of CNY 3.94 million in the previous year[31]. - The company reported a total cash outflow from financing activities of 1,184,902,817.65 CNY, compared to 843,829,507.71 CNY in the previous period[130]. - The cash flow from operating activities showed a total inflow of 1,519,571,580.40 CNY, down from 1,654,928,509.04 CNY in the previous period[129]. - The company received 30,870,000.00 CNY from investment absorption during the period[133]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 4,006,797,160.77, a slight decrease of 0.30% from CNY 4,018,885,380.37 at the end of the previous year[16]. - Long-term borrowings rose by 41.76% to 482 million RMB from 340 million RMB, driven by increased borrowing for real estate projects[36]. - The total liabilities decreased from ¥2,880,257,297.36 to ¥2,842,748,088.36, a decrease of around 1.3%[117]. - The company reported a total of 3,063,284,657.50 RMB in current assets as of June 30, 2015, slightly down from 3,065,765,552.42 RMB at the beginning of the period[116]. - The company’s total liabilities and shareholders' equity will be detailed in the upcoming financial reports, indicating ongoing financial assessments[114]. Shareholder Information - The total number of shareholders as of the end of the reporting period is 67,875[101]. - The largest shareholder, Suzhou Wuzhong Investment Holding Co., Ltd., holds 122,795,762 shares, accounting for 19.53% of total shares[104]. - The company has 101,610,762 shares under lock-up conditions, which will be released on December 28, 2016[100]. - The total number of shares with limited sale conditions is 106,510,762, accounting for 16.94% of the total shares[144]. - The company has a total of 522,089,238 shares with no sale restrictions, representing 83.06% of the total shares[144]. Research and Development - The company has made progress in R&D, with a new anti-cancer drug in clinical trials and recognition for its innovative projects[26]. - The Phase III clinical trial for the new anti-cancer drug, recombinant human vascular endothelial inhibitor injection, has enrolled 540 cases as of the reporting period[88]. - The company is actively working on improving its clinical trial data management and statistical analysis processes[88]. - The company plans to announce future market expansion and product development in the pharmaceutical sector[88]. - The company has received GMP certification for raw materials including Nicorandil and Lansoprazole[89]. Corporate Governance - The company reappointed Lixin Certified Public Accountants for the 2015 audit based on the 2014 annual shareholders' meeting resolution[79]. - The company was selected for the Shanghai Stock Exchange's corporate governance sector and its stock was included in the SSE Corporate Governance Index sample stocks[81]. - The company has strengthened its internal control systems and improved information disclosure quality during the reporting period[81]. - The board of directors has effectively overseen strategic planning and operational management, ensuring smooth daily operations[82]. - The company has maintained a robust investor relations management system, enhancing communication with investors through various channels[84]. Profit Distribution and Incentives - The company did not propose any profit distribution plan or capital reserve transfer to share capital during the reporting period[3]. - The company plans to distribute a cash dividend of CNY 0.20 per share, totaling CNY 12,572,000.00, based on a total share capital of 628,600,000 shares[57]. - The company implemented a restricted stock incentive plan, granting a total of 4,900,000 shares to 27 key personnel, including senior management and core technical staff[66]. - The actual amortized cost of the stock incentive for the reporting period was 5.76 million CNY[69]. - The company has committed to avoid related party transactions that could harm the interests of shareholders[78]. Market and Sales Performance - Domestic sales revenue decreased by 15.03% to CNY 105,920.98 million, while foreign sales increased by 10.46% to CNY 31,345.35 million[46]. - The pharmaceutical segment reported revenue of CNY 419.87 million, an increase of CNY 37.69 million or 9.86% year-on-year, with a gross profit of CNY 132.66 million, up 3.81%[25]. - The real estate segment generated revenue of CNY 151.16 million, a significant decrease of CNY 175.01 million or 53.66% year-on-year, with a gross profit decline of 52.44%[27]. - The company plans to achieve a main business income of 3.2 billion RMB for the fiscal year 2015, maintaining cost ratios similar to 2014[37]. - The company has ongoing real estate projects with a total planned investment of 270 million RMB, with several projects in various stages of development[42].